SINOMED(SH:688108) Sou Hu Cai Jing·2025-12-30 00:38Core Viewpoint - Sino Medical (688108) experienced a decline in stock price, closing at 20.3 yuan on December 29, 2025, down 2.82% with a trading volume of 327,400 shares and a total transaction value of 675 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Sino Medical reported a main revenue of 364 million yuan, an increase of 14.24% year-on-year [3] - The net profit attributable to shareholders reached 21.12 million yuan, showing a significant increase of 293.46% year-on-year [3] - The net profit excluding non-recurring items was 13.91 million yuan, up 148.63% year-on-year [3] - In Q3 2025, the company achieved a quarterly main revenue of 123 million yuan, a year-on-year increase of 17.73% [3] - The quarterly net profit attributable to shareholders was 7.28 million yuan, reflecting a year-on-year increase of 150.51% [3] - The quarterly net profit excluding non-recurring items was 5.93 million yuan, up 137.04% year-on-year [3] - The company's debt ratio stands at 30.4%, with financial expenses of 3.22 million yuan and a gross profit margin of 65.7% [3] Group 2: Market Activity - On December 29, 2025, the net inflow of main funds was 7.93 million yuan, accounting for 1.17% of the total transaction value [1] - Retail investors experienced a net outflow of 63.53 million yuan, representing 9.41% of the total transaction value [1] - Over the past five days, the financing buy amounted to 83.84 million yuan, while financing repayment was 49.41 million yuan, resulting in a net financing buy of 34.43 million yuan [2] - The total financing and securities balance is 750 million yuan [2] Group 3: Company Overview - Sino Medical focuses on the research, development, production, and sales of high-end interventional medical devices, with product lines covering cardiovascular, cerebrovascular, and structural heart disease treatment areas [3] - The company's core product is the BuMA biodegradable drug-coated coronary stent system, which is designed and developed in-house and holds international intellectual property rights [3]